Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity

SR. Williamson, O. Hes, K. Trpkov, A. Aggarwal, A. Satapathy, S. Mishra, S. Sharma, A. Sangoi, L. Cheng, M. Akgul, M. Idrees, A. Levin, S. Sadasivan, P. San Miguel Fraile, J. Rogala, E. Comperat, DM. Berney, S. Bulimbasic, JK. McKenney, S. Jha,...

. 2023 ; 82 (2) : 296-304. [pub] 20221018

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22032064

Low-grade oncocytic tumour (LOT) of the kidney has recently emerged as a potential novel tumour type. Despite similarity to oncocytoma or eosinophilic chromophobe renal cell carcinoma, it shows diffuse keratin 7 immunohistochemistry (IHC) and negative KIT (CD117), which differs from both. We aimed to identify the molecular characteristics of these tumours. Seventeen tumours (one male, 16 female, nine previously published) fitting the original description of this entity (solid eosinophilic cell morphology, often with areas of tumour cells loosely stretched in oedematous stroma, and the above IHC features) were analysed with a next-generation sequencing panel of 324 cancer-associated genes from formalin-fixed, paraffin-embedded tissue. All tumours harboured at least one alteration in either TSC1 (n = 7, 41%), TSC2 (n = 2, 12%), MTOR (n = 5, 29%) or PIK3CA (n = 4, 24%). Four tumours harboured a second alteration, including two NF2, one each in conjunction with MTOR and TSC2 alterations, one PTEN with TSC1 alteration and one tumour with both MTOR and TSC1 alterations. No other renal cancer-related or recurring gene alterations were identified. In addition to the previously described IHC findings, 16 of 16 were positive for GATA3. Eleven patients with follow-up had no metastases or recurrent tumours. Recurrent tuberous sclerosis/MTOR pathway gene alterations in LOT support its consideration as a distinct morphological, immunohistochemical and genetic entity. PIK3CA is another pathway member that may be altered in these tumours. Further study will be necessary to determine whether tumour behaviour or syndromic associations differ from those of oncocytoma and chromophobe carcinoma, warranting different clinical consideration.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032064
003      
CZ-PrNML
005      
20230131150720.0
007      
ta
008      
230120s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/his.14816 $2 doi
035    __
$a (PubMed)36208048
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Williamson, Sean R $u Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA $1 https://orcid.org/0000000238981460
245    10
$a Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity / $c SR. Williamson, O. Hes, K. Trpkov, A. Aggarwal, A. Satapathy, S. Mishra, S. Sharma, A. Sangoi, L. Cheng, M. Akgul, M. Idrees, A. Levin, S. Sadasivan, P. San Miguel Fraile, J. Rogala, E. Comperat, DM. Berney, S. Bulimbasic, JK. McKenney, S. Jha, NY. Sampat, SK. Mohanty
520    9_
$a Low-grade oncocytic tumour (LOT) of the kidney has recently emerged as a potential novel tumour type. Despite similarity to oncocytoma or eosinophilic chromophobe renal cell carcinoma, it shows diffuse keratin 7 immunohistochemistry (IHC) and negative KIT (CD117), which differs from both. We aimed to identify the molecular characteristics of these tumours. Seventeen tumours (one male, 16 female, nine previously published) fitting the original description of this entity (solid eosinophilic cell morphology, often with areas of tumour cells loosely stretched in oedematous stroma, and the above IHC features) were analysed with a next-generation sequencing panel of 324 cancer-associated genes from formalin-fixed, paraffin-embedded tissue. All tumours harboured at least one alteration in either TSC1 (n = 7, 41%), TSC2 (n = 2, 12%), MTOR (n = 5, 29%) or PIK3CA (n = 4, 24%). Four tumours harboured a second alteration, including two NF2, one each in conjunction with MTOR and TSC2 alterations, one PTEN with TSC1 alteration and one tumour with both MTOR and TSC1 alterations. No other renal cancer-related or recurring gene alterations were identified. In addition to the previously described IHC findings, 16 of 16 were positive for GATA3. Eleven patients with follow-up had no metastases or recurrent tumours. Recurrent tuberous sclerosis/MTOR pathway gene alterations in LOT support its consideration as a distinct morphological, immunohistochemical and genetic entity. PIK3CA is another pathway member that may be altered in these tumours. Further study will be necessary to determine whether tumour behaviour or syndromic associations differ from those of oncocytoma and chromophobe carcinoma, warranting different clinical consideration.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lokální recidiva nádoru $7 D009364
650    12
$a karcinom z renálních buněk $x genetika $7 D002292
650    12
$a nádory ledvin $x genetika $7 D007680
650    _2
$a mutace $7 D009154
650    12
$a oxyfilní adenom $x genetika $7 D018249
650    _2
$a ledviny $7 D007668
650    _2
$a TOR serin-threoninkinasy $x genetika $7 D058570
650    _2
$a transkripční faktor GATA3 $x genetika $7 D050990
650    _2
$a fosfatidylinositol-3-kinasy třídy I $x genetika $7 D058534
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hes, Ondrej $u Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000232363127
700    1_
$a Trpkov, Kiril $u Department of Pathology and Laboratory Medicine, Alberta Precision Labs and University of Calgary, Calgary, Alberta, Canada $1 https://orcid.org/0000000331428846
700    1_
$a Aggarwal, Aditi $u CORE Diagnostics, Gurgaon, Haryana, India
700    1_
$a Satapathy, Abhishek $u Advanced Medical Research Institute, Bhubaneswar, Odisha, India
700    1_
$a Mishra, Sourav $u Advanced Medical Research Institute, Bhubaneswar, Odisha, India
700    1_
$a Sharma, Shivani $u CORE Diagnostics, Gurgaon, Haryana, India
700    1_
$a Sangoi, Ankur $u Department of Pathology, El Camino Hospital, Mountain View, CA, USA $1 https://orcid.org/0000000308748964
700    1_
$a Cheng, Liang $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA $1 https://orcid.org/0000000160495293
700    1_
$a Akgul, Mahmut $u Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA
700    1_
$a Idrees, Muhammad $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA $1 https://orcid.org/0000000166116389
700    1_
$a Levin, Albert $u Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA
700    1_
$a Sadasivan, Sudha $u Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA
700    1_
$a San Miguel Fraile, Pilar $u Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain
700    1_
$a Rogala, Joanna $u Regional Specialist Hospital, Wroclaw, Poland
700    1_
$a Comperat, Eva $u Department of Pathology, Hôpital Tenon, Sorbonne University, Paris VI, Paris, France $1 https://orcid.org/000000018488543X
700    1_
$a Berney, Daniel M $u Department of Cellular Pathology, Bartshealth NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK $1 https://orcid.org/0000000154748696
700    1_
$a Bulimbasic, Stela $u Department of Pathology, School of Medicine, Zagreb, Croatia
700    1_
$a McKenney, Jesse K $u Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA $1 https://orcid.org/0000000308511465
700    1_
$a Jha, Shilpy $u Advanced Medical Research Institute, Bhubaneswar, Odisha, India
700    1_
$a Sampat, Nakul Y $u Advanced Medical Research Institute, Bhubaneswar, Odisha, India
700    1_
$a Mohanty, Sambit K $u CORE Diagnostics, Gurgaon, Haryana, India $u Advanced Medical Research Institute, Bhubaneswar, Odisha, India
773    0_
$w MED00002043 $t Histopathology $x 1365-2559 $g Roč. 82, č. 2 (2023), s. 296-304
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36208048 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131150716 $b ABA008
999    __
$a ok $b bmc $g 1891064 $s 1183399
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 82 $c 2 $d 296-304 $e 20221018 $i 1365-2559 $m Histopathology $n Histopathology $x MED00002043
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Archiving options